Nasdaq · Common Stock · Biological Products, (No Diagnostic Substances)
American biotechnology company
29 entities across 19 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-02-20 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Moderna Australia Pty Ltd | Australia | |
| Moderna Biopharma Canada Corporation | Canada | |
| Moderna Biotech Distributor UK Ltd. | United Kingdom | |
| Moderna Biotech Manufacturing UK Ltd. | United Kingdom | |
| Moderna Biotech Securities, Inc. | Massachusetts | |
| Moderna Biotech Singapore Pte. Ltd. | Singapore | |
| Moderna Biotech Spain, S.L.U. | Spain | |
| Moderna Biotech UK Limited | United Kingdom | |
| Moderna Charitable Foundation, Inc. | Delaware | |
| Moderna Clinical Supply Distributor, LLC | Delaware | |
| Moderna Enzymatics Co., Ltd. | Japan | |
| Moderna France | France | |
| Moderna Germany GmbH | Germany | |
| Moderna Hong Kong Limited | Hong Kong | |
| Moderna Italy S.r.l. | Italy | |
| Moderna Japan Co., Ltd. | Japan | |
| Moderna Korea Limited | South Korea | |
| Moderna Manufacturing Australia Pty Ltd. | Australia | |
| Moderna Manufacturing Canada Corp. | Canada | |
| Moderna Netherlands B.V. | Netherlands | |
| Moderna Norway AS | Norway | |
| Moderna Norwood Real Estate LLC | Delaware | |
| Moderna Poland sp. z o.o. | Poland | |
| Moderna Services, Inc. | Delaware | |
| Moderna Sweden AB | Sweden | |
| Moderna Switzerland GmbH | Switzerland | |
| ModernaTX, Inc. | Delaware | |
| Moderna Taiwan Co., Ltd | Taiwan | |
| Moderna US, Inc. | Delaware |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $803.4M | −$747.1M | $2.0B | — | 381,000,000 |
| FY2021 | $18.5B | $12.2B | $13.3B | — | 431,000,000 |
| FY2022 | $19.3B | $8.4B | $4.6B | — | 416,000,000 |
| FY2023 | $6.8B | −$4.7B | −$3.8B | — | 382,000,000 |
| FY2024 | $3.2B | −$3.6B | −$4.1B | — | 384,000,000 |
| FY2025 | $1.9B | −$2.8B | −$2.1B | — | 389,000,000 |
16 institutions tracked — 10 added, 5 reduced, 1 opened a new position, 1 sold out.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| FMR LLC | Active fund | 51,859,891 | +6,187,867 | $3.6B |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 5,589,560 | +4,850,982 | $391.4M |
| Capital World Investors | Active fund | 22,276,996 | +3,579,302 | $1.6B |
| BAILLIE GIFFORD & CO | Value | 18,206,778 | −1,779,098 | $1.3B |
| MORGAN STANLEY | Active fund | 9,538,094 | +1,066,831 | $668.0M |
| JPMORGAN CHASE & CO | Active fund | 1,274,252 | −1,041,649 | $90.0M |
| BlackRock, Inc. | Index | 30,599,409 | +963,533 | $2.1B |
| STATE STREET CORP | Index | 15,726,193 | +864,784 | $1.1B |
| CITADEL ADVISORS LLC | Hedge fund | 6,232,496 | −832,874 | $436.5M |
| Point72 Asset Management, L.P. | Hedge fund | 221,600 | −492,644 | $15.5M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 479,141 | +440,826 | $33.6M |
| BANK OF AMERICA CORP /DE/ | Active fund | 1,409,679 | +423,319 | $98.7M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 9,710,335 | +275,203 | $678.8M |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 2,461,574 | +103,977 | $172.4M |
| Bridgewater Associates, LP | Hedge fund | 11,527 | −63,295 | $807,236 |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Moderna, Inc. files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
